AzTrials
AzTrials

Abdominal Aortic AneurysmNEOVASNCT05823519

Neck Evolution With Ovation in Spain

An observational study of Abdominal Aortic Aneurysm, run by DGM Vascular at 9 sites in Spain.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a multicenter, observational, prospective, single arm registry using Ovation Alto Endograft. A minimum of 50 up to a maximum of 120 subjects undergoing endovascular repair with Ovation Alto endograft will be enrolled and followed procedurally to discharge, at 1month, 6 months, 1 year and yearly afterward up to… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Abdominal Aortic Aneurysm
What is being tested?
Endologix Ovation Alto Endograft
Type of treatment
Medical device
How many people
120 participants
Where
9 sitesSpain
Study dates
1 Jun 2022to 1 Jan 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Male or female at least 18 years old with aortic abdominal aneurysm with characteristics within the IFU of de device

Who may be able to join

  • Male or female at least 18 years old.
  • Subject has signed informed consent for data release.
  • Subjects with de novo infrarenal AAA /aorto-iliac AAA and eligible for endovascular Abdominal Aortic Aneurysm Repair with the Ovation Alto Endograft according to current IFU.

Who cannot join

  • Currently participating in another study where primary endpoint has not been reached yet.
  • Currently participating in another study with the same devices and/or the same primary endpoint.
  • Known allergy to any of the device components.
  • Pregnant (females of childbearing potential only).

Trial locations and contacts

9 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Manuel Alonso Pérez, MD contact

985 10 80 00

manuel.alonsop@sespa.es

9 sites in 1 country

Spain9 sites, 9 recruiting
  • Hospital Universitario De Cruces

    Barakaldo, Bizkaia, 48903

    Juan Luis Fonseca Legrand, MD

    Juan Luis Fonseca Legrand, MD

    Recruiting
  • Hospital De La Santa Creu I Sant Pau

    Barcelona, 08025

    Jaume Felix Dilmé Muñoz, MD

    Jaume Felix Dilmé Muñoz, MD

    Recruiting
  • Hospital Universitario Germans Trias i Pujol

    Barcelona, 08916

    Secundino Llagostera Pujol, MD

    Secundino Llagostera Pujol, MD

    Recruiting
  • Hospital Universitario De Burgos

    Burgos, Castille and León, 09006

    Ignacio Agundéz Gómez, MD

    Ignacio Agundéz Gómez, MD

    Recruiting
  • Hospital Universitario De Cabueñes

    Gijón, Principality of Asturias, 33394

    Luis Javier Álvarez Fernández, MD

    Luis Javier Álvarez Fernández, MD

    Recruiting
  • Hospital Universitario De Girona Dr. Josep Trueta

    Girona, Barcelona, 17007

    Omar Aitor Andrés Navarro, MD

    Omar Aitor Andrés Navarro, MD

    Recruiting
  • Hospital Universitari Son Espases

    Palma de Mallorca, Balearic Islands, 07120

    Pascual Lozano Vilardell, MD

    Pascual Lozano Vilardell, MD

    Recruiting
  • Hospital Universitario de Salamanca

    Salamanca, Castille and León, 37007

    Francisco Santiago Lozano Sánchez, MD

    Francisco Santiago Lozano Sánchez, MD

    Recruiting
  • Hospital General Universitario De Toledo

    Toledo, Castille-La Mancha, 45007

    Antonio Orgaz Pérez-Grueso, MD

    Antonio Orgaz Pérez-Grueso, MD

    Recruiting

Other trials in Spain

About this study

This is a multicenter, observational, prospective, single arm registry using Ovation Alto Endograft. A minimum of 50 up to a maximum of 120 subjects undergoing endovascular repair with Ovation Alto endograft will be enrolled and followed procedurally to discharge, at 1month, 6 months, 1 year and yearly afterward up to 3 years. This registry of Ovation Alto endograft will provide further assessment to confirm continuing safety and effectiveness of the graft and to confirm the stability of the neck diameter over time when treated with this device.

Read the detailed description

Abdominal Aortic Aneurysm (AAA) is a widespread disease with a high mortality rate in case of ruptures, with a sizable number of patients dying before a diagnosis is made. Approximately 32.000 patients are newly diagnosed with AAA and about 44.000 repair procedures are performed in the US every year. It is estimated that up to 2.000.000 subjects are living with an undiagnosed AAA with a greater incidence in the elderly population >65 years. Risk factors include smoking, hypertension, hypercholesterolemia, gender (men/women ratio 5:1) and family history (15-20%) increase risk amongst first degree relatives. The rupture risk increases with age and concomitant hypertension as well as current tobacco use and presence of other cardio-vascular diseases. AAA is clinically defined as a focal dilatation of the aorta causing a diameter increase of >50% of the expected normal diameter. Although any artery may develop an aneurysm, they are most commonly observed in the infrarenal abdominal aorta, thoracic aorta, popliteal artery and common iliac artery. The concomitants risks related to aneurysms are rupture and thrombus migration. Aneurysms slowly and continually grow in size leading to the aneurysm bursts. The larger an aneurysm becomes, the likelihood of eventual rupture may appear. The natural outcomes of aortic aneurysms is to enlarge and rupture. Other potential complications of the aneurysm include compression of adjacent organs which may result in aortoenteric fistula, or aortocaval fistula. If the thrombus embolizes and flows down the blood stream, this can induce acute or chronic arterial obliteration of the lower limbs.The risk of rupture is weighed against the risk of perioperative morbidity. The United Kingdom Small Aneurysm trial (UKSAT) reported 103 aneurysm ruptures in 2,257 subjects over a period of seven years, with an annual rupture rate of 2.2%. The decision to treat a patient that presents with an asymptomatic aneurysm is primarily dependent upon the size of the aneurysm. Current Society for Vascular Surgery (SVS) practice guidelines recommend surveillance for most subjects with a fusiform AAA in the range of 4.0 to 5.4cm in maximum diameter; therefore, surgical repair of abdominal aneurysms of 5.5 cm or greater in diameter is recommended in healthy subjects, as it is repair of saccular aneurysms. With the development of endovascular treatment options in recent years, treatment of AAA has become a viable option for patients with a high pre-operative risk. Endovascular Aneurysm Repair (EVAR) has become the treatment strategy of choice for AAA. Nowadays, the most important limit to the effectiveness of this technique is represented by complex anatomical situations, especially regarding the morphology of the proximal sealing zone. In previously published studies, the use of EVAR outside the specific instructions for use (IFU) of the devices for patients with challenging proximal aortic necks yielded a non-negligible rate of immediate complications and re-interventions. The Ovation iX and Alto endografts represent a new technical step in EVAR. This new device separates fixation from sealing: fixation is guaranteed by suprarenal stent and anchors, while sealing is ensured by inflatable rings filled with a low-viscosity, non-embolic, radiopaque fill polymer. This unique characteristic allows this graft to isolate aortic neck from blood pressure without radial force, with the result of very low ratios of Type 1 Endoleaks and absence aortic neck growing. The presence of the polymer-filled network also allows the graft to conform to the patient's aortic neck, providing precise and reliable sealing in a great variety of anatomies. Different from common stent-graft platforms, separation between fixation and sealing ensures that stent and fabric do not compete in the Ovation endograft for the same space within the shaft, and an ultra-low-profile delivery system can be achieved, allowing the treatment of patients presenting a wide range of iliac access.

Being tested
Endologix Ovation Alto Endograft
Keywords
Alto Endograft, Abdominal Aortic Aneurysm
Medical subject headings
Aortic Aneurysm, Abdominal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Endologix Ovation Alto EndograftDevice

    Implantation of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms

Study groups in NCT05823519
Study groupRoleWhat they receive
SINGLE ArmObservational, Multicenter, Prospective, single arm registry study with consecutive, eligible patient enrollment at each site. Subjects will be followed procedurally to discharge, and as per institutional standard of care thereafter through to 3 years (total follow-up commitment), with follow up including Computed tomography angiography (CTA) study and Case Report Form data at 1 month, 6 months, 1 years, 2 years and 3 years, closing at this time the study primary endpoint.
Receives: Device: Endologix Ovation Alto Endograft

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Post-implant infrarenal aneurysm's neck grow evaluation

    The neck diameter will be measured on Computed Tomography Angiography (CTA) at 0mm (lowest renal artery), 5mm, 10mm, 15mm and 20mm. No type I or III endoleak. No clinically significant migration (>5mm). No Aneurysm enlargement (>5mm)

    Measured: 30 days

  2. Post-implant infrarenal aneurysm's neck grow evaluation

    The neck diameter will be measured on Computed Tomography Angiography (CTA) at 0mm (lowest renal artery), 5mm, 10mm, 15mm and 20mm. No type I or III endoleak. No clinically significant migration (>5mm). No Aneurysm enlargement (>5mm)

    Measured: 6 months

  3. Post-implant infrarenal aneurysm's neck grow evaluation

    The neck diameter will be measured on Computed Tomography Angiography (CTA) at 0mm (lowest renal artery), 5mm, 10mm, 15mm and 20mm. No type I or III endoleak. No clinically significant migration (>5mm). No Aneurysm enlargement (>5mm)

    Measured: 1 year

  4. Post-implant infrarenal aneurysm's neck grow evaluation

    The neck diameter will be measured on Computed Tomography Angiography (CTA) at 0mm (lowest renal artery), 5mm, 10mm, 15mm and 20mm. No type I or III endoleak. No clinically significant migration (>5mm). No Aneurysm enlargement (>5mm)

    Measured: 2 years

  5. Post-implant infrarenal aneurysm's neck grow evaluation

    The neck diameter will be measured on Computed Tomography Angiography (CTA) at 0mm (lowest renal artery), 5mm, 10mm, 15mm and 20mm. No type I or III endoleak. No clinically significant migration (>5mm). No Aneurysm enlargement (>5mm)

    Measured: 3 years

Secondary outcomes (5)
  1. Procedural technical success

    Immediate procedural technical success

    Measured: Immediately after the procedure

  2. Aneurysm evaluation

    No Aneurysm rupture

    Measured: 3 years

  3. Related mortality

    AAA-related mortality

    Measured: 3 years

  4. Secondary Evaluations

    Conversion to open surgical

    Measured: 3 years

  5. Polymer leak

    No polymer leak during and after implant

    Measured: 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Apr 2023
  2. Study start1 Jun 2022
  3. Primary completion1 Jan 2024 (estimated)
  4. Study completion1 Jan 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05823519
Sponsor's protocol ID
NEOVAS
Acronym
NEOVAS
Status last verified
Mar 2023
First submitted
14 Mar 2023
Last updated
21 Apr 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Abdominal Aortic Aneurysm, run by DGM Vascular at 9 sites in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 9 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Manuel Alonso Pérez, MD (985 10 80 00, manuel.alonsop@sespa.es), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Post-implant infrarenal aneurysm's neck grow evaluation (time frame: 30 days). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2023; AzTrials last refreshed its copy on 26 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in